LongeVC aims to raise a $250M fund to invest in Asian longevity and biotech startups

Latvian LongeVC is planning to raise a $250M fund to invest in Asian longevity and biotech startups. LongeVC also intends to raise investments for LongeVC's sister fund, Ani VC, which will focus on animal longevity and pet health.

According to the fund, citing a report by InsightAce Analytic, the global market for longevity and anti-senescence therapy was valued at over $27,1Bln in 2023 and is expected to reach $44,9Bln by 2031. 

Founded in 2016 by Garri Zmudze, Sergey Jakimov, and Ilya Suharenko, LongeVC is a venture company with offices in Riga and Lugano (Switzerland). A €35M fund backs startups at the early and seed stage startups in the US and Europe.

More

Lithuanian Masiva Group acquires Contribee